Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant must have chronic plaque psoriasis for at least 6 months.
You may not be if
Participant must not be breastfeeding or nursing woman.
Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.
Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.
Participant must not have any other skin conditions (excluding psoriasis).
Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).
Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.
Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).
Clareo Health | A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
